Drugs / ION775
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07604974 | May 2026 → Sep 2027 expected | hypertriglyceridemia | Ionis Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-10-07 | Ionis Pharmaceuticals | Results Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day ionis.com ↗
ION775 achieved substantial, durable and sustained reductions in apoC-III and fasting triglycerides with favorable safety and tolerability in healthy volunteers with moderately elevated triglycerides. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-10-07 | Ionis Pharmaceuticals | Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day ionis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ION775 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07604974 ↗ |
| Route | Subcutaneous | “ION775 will be administered by SC injection.” NCT07604974 ↗ |